Seres Therapeutics, Inc. (MCRB)
| Market Cap | 50.80M -69.3% |
| Revenue (ttm) | 1.88M |
| Net Income | -22.46M |
| EPS | -2.41 |
| Shares Out | 9.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,489 |
| Open | 4.92 |
| Previous Close | 4.95 |
| Day's Range | 4.80 - 5.14 |
| 52-Week Range | 4.32 - 29.98 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+232.68%) |
| Earnings Date | Aug 5, 2026 |
About MCRB
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MCRB stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 232.68% from the latest price.
News
Seres Therapeutics files $300M mixed securities shelf
16:36 EDT Seres Therapeutics (MCRB) files $300M mixed securities shelf
Seres Therapeutics Registration statement: Registration filing
Seres Therapeutics filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
Seres Therapeutics reports Q2 EPS 47c, consensus ($2.18)
Reports Q2 revenue $736,000, consensus $179,000. “We are very pleased with the recent progress at Seres, including the positive topline data from the investigator-sponsored trial of SER-155 in irEC co...
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
Recently announced 80% of SER-155 recipients achieved immunosuppressive-free clinical response at day 15 for immune checkpoint inhibitor-related enterocolitis (irEC) in the investigator-sponsored tria...
Seres Therapeutics Earnings release: Q2 2026
Seres Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Seres Therapeutics Quarterly report: Q2 2026
Seres Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Seres Therapeutics Transcript: Study result
SER-155 showed an 80% immunosuppressive-free response rate in moderate to severe irEC, with rapid and durable symptom improvement and favorable safety. Biomarker and pharmacology data support its mechanism, and a phase II trial is planned to further evaluate its potential.
Seres Therapeutics Press release: Study result
Seres Therapeutics issued a press release on July 8, 2026, disclosing material business information to investors.
Seres Therapeutics Slides: Study result
Seres Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 8, 2026.
Seres Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and an amendment to the incentive award plan, with all proposals approved. No questions were submitted by stockholders, and final voting results will be published in a Form 8-K.
Seres Therapeutics announces top-line results from SER-155 trial
Seres Therapeutics (MCRB) announced top-line results from an investigator-sponsored trial evaluating SER-155 in patients with irEC. The study, conducted at MSK, evaluated SER-155 in 15 patients with m...
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kett...
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line res...
Seres Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Seres Therapeutics (MCRB) with a Buy rating and $12 price target Seres is a clinical stage biotech company developing live biotherapeutic products for inflammator...
Seres Therapeutics announces two transactions
Seres Therapeutics (MCRB) announced two transactions to extend its expected operating cash runway well into the first quarter of 2027. Seres entered into an amendment to the prior asset purchase…
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones
Seres Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The presentation highlighted advances in microbiome-based therapeutics, including a phase II-ready asset with strong efficacy data and the integration of generative AI into drug development. Near-term milestones include key clinical readouts and strategic partnerships, with a focus on high-need patient populations.
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C.
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biother...
Seres Therapeutics Earnings release: Q1 2026
Seres Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Seres Therapeutics Quarterly report: Q1 2026
Seres Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomar...
Seres Therapeutics Proxy statement: Proxy filing
Seres Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Seres Therapeutics Proxy statement: Proxy filing
Seres Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Seres Therapeutics announces three presentations at 2026 ESCMID congress
Seres Therapeutics (MCRB) announced three presentations at the 2026 European Society of Clinical Microbiology and Infectious Diseases, ESCMID, global congress, taking place April 17-21 in Munich, Germ...